Fractyl Health Inc., a company focused on innovative metabolic therapeutics, has presented promising preclinical data from their Rejuva smart GLP-1 gene therapy platform at the ASGCT 2025 Annual Meeting. The research highlights the potential of RJVA-001, a gene therapy designed to restore natural physiologic signaling in the pancreas, offering durable disease modification in diabetes and obesity. This approach aims to achieve these effects without the high systemic drug exposure associated with current GLP-1 therapies, thus minimizing side effects. Preclinical models have demonstrated RJVA-001's superior potency, durability, and convenience, along with a potentially improved tolerability profile. The therapy showed targeted delivery and strong efficacy in animal models, and no toxicity was observed. Fractyl Health is advancing toward first-in-human studies, with a clinical trial application expected by June 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.